Grace Therapeutics, Inc.
GRCE
$2.14
$0.020.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -96.07% | 18.55% | 55.28% | 32.62% | 9.91% |
| Total Depreciation and Amortization | -12.50% | 0.00% | 16.67% | 20.00% | 60.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 466.40% | 68.30% | -113.33% | -27.62% | -2,944.34% |
| Change in Net Operating Assets | -631.75% | 110.23% | -131.12% | -142.11% | -87.19% |
| Cash from Operations | 21.51% | 40.49% | 27.85% | -1.68% | -35.30% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Investing | -- | -- | -100.00% | 171.43% | -83.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -73.06% | -73.06% | 11,652.47% | 9,158.64% | 99.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 66.18% | -698.77% | -698.77% | -698.77% |
| Cash from Financing | -70.52% | -73.54% | -- | -- | 86.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,122.75% | -491.28% | 201.70% | 114.42% | 127.29% |